CDH5 and neoplasm: In mice with a mutation in the VEGFR2-Tyr949 site (tyrosine–phenylalanine) [38], phosphorylation of VE-cadherin is reduced and junctions maintain their integrity in pathological settings characterised by elevated VEGF-A, such as tumours.